|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||5.83 / 11.62|
Phase 1b/2a study combines MedImmune's MEDI0457 (INO-3112), a DNA-based immunotherapy targeting HPV-associated cancer, and durvalumab, an immune checkpoint (PD-L1) inhibitor
Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.
Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer
The vaccine study showed that 95% of subjects generated an Ebola-specific antibody immune response.
Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 17th expiration.
Former Novartis CFO brings finance, fundraising and M&A experience to Inovio
Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
These heavily shorted stocks could get squeezed higher if they report positive earnings this week.
Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.
SynCon WT1 and PSMA antigens join hTERT in INO-5401, Inovio's cancer product planned for immuno-oncology combination study
These four biotech stocks have been moving on some interesting news and clinical results.
Other movers include Incyte, Achillion and Inovio.
Jim Cramer is bullish on Hershey, Nvidia, Accenture, Cheniere Energy. He's bearish on Emerge Energy and Seaspan.
Don't get upended by the rhetoric. The transports are confirming, banks are solid, there's a genuine uptick in commerce and earnings are strong, says Jim Cramer.
Inovio to receive up to $50 million in upfront and near term payments and equity investment
Jim Cramer names a few of his favorite things: housing, bank, material and tech stocks, oil, copper and deregulation.
Jim Cramer is bullish on Chesapeake Energy and some bank stocks. But he's bearish on Inovio Pharmaceutical.